Compare Abbott Laboratories (ABT) vs Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Direxion NASDAQ 100 Equal Weighted Index Shares — how do they compare? Abbott Laboratories trades at $95.54 (market cap $166.94B), while Direxion NASDAQ 100 Equal Weighted Index Shares trades at $118.7. The key difference: Abbott Laboratories pays a 2.63% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none, and Direxion NASDAQ 100 Equal Weighted Index Shares is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | QQQE | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $136.62 | $122.72 |
52-Week Low | $82.57 | $96.06 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
QQQE trades at $120.89, up 0.62% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF provides equal-weighted exposure to the Nasdaq-100, reducing concentration risk compared to market-cap-weighted peers. Recent news highlights its appeal for diversified growth exposure amid SpaceX's upcoming Nasdaq-100 inclusion (Zacks Investment Research, 2026-06-29).
Outlook remains positive due to defensive positioning and reduced mega-cap reliance, though macroeconomic headwinds and market volatility pose risks. The equal-weight strategy may offer better risk-adjusted returns in a flat or correcting market regime, as noted by analysts (Seeking Alpha, 2026-04-13).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →
